Next-Generation Sequencing
ESR1 Mutation Testing May be Informative for Personalizing SERD Treatment, SABCS Studies Show
Premium
In two studies, testing for ESR1 mutations identified patients who responded particularly well to SERDs.
SABCS Study Highlights Importance of Ranking Biomarker Evidence in Genomic Test Reports
The study showed that metastatic breast cancer patients are more likely to benefit from precision cancer drugs matched based on biomarkers with strong actionability evidence.
Local Cancer Genomic Profiling Options Grow, Though Central Labs Will Likely Keep Major Role
Premium
As economic and practical challenges of next-gen sequencing have eased in recent years, more groups are bringing comprehensive cancer genomic testing in house.
Postsurgical ctDNA Analysis Predicts Adjuvant Chemotherapy Benefit in NSCLC
Research out of Geneseeq and the Chinese Academy of Medical Sciences shows the value of ctDNA analysis to guide treatment and predict disease recurrence.
Geneseeq Multi-Biomarker Approach Predicts EGFR-Mutated NSCLC Patients' Adjuvant Therapy Benefit
Premium
Geneseeq collaborated with researchers in China to generate three molecularly defined subgroups to guide adjuvant NSCLC treatment with either TKIs or chemotherapy.